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Blood-based biomarkers for traumatic brain injury (TBI) have been investigated and proposed for decades, yet
the current clinical assessment of TBI is largely based on clinical symptoms that can vary widely amongst pa-
tients, and have significant overlapwith unrelated disease states. A careful reviewof current treatment guidelines
for TBI further highlights the potential utility of a blood-based TBI biomarker panel in augmenting clinical deci-
sion making. Numerous expert reviews on blood-based TBI biomarkers have been published but a close look at
the methods used and the astonishing paucity of validation and quality control data has not been undertaken
from the vantage point of the clinical laboratory. Further, the field of blood-based TBI biomarker research has
failed to adequately examine sex and gender differences between men and women with respect to the clinical
care settings, as well as differences in physiological outcomes of TBI biomarker studies. Discussions of tried-
and-true laboratory techniques in addition to a few new ones already operating in the clinical laboratory are
summarized with a consideration of their utility in TBI biomarker assessment. In the context of TBI biomarkers,
the central concerns discussed in this review are the readiness of the clinical laboratory, the willingness of the
research environment and the inherent ability of each to radically affect patient outcomes in TBI.
© 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
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Introduction
Blood-based biomarkers for traumatic brain injury (TBI) have been
investigated and proposed for decades. In recent years, there has been
increased focus on mild TBI and concussion with substantial media
coverage surrounding concussion in sports [1] and the recognition of
TBI as the defining injury for veterans of the Iraq and Afghanistan
wars [2]. The current clinical assessment of TBI is largely based on clin-
ical symptoms that can vary widely amongst patients and have signifi-
cant overlap with unrelated disease states [1,3,4].
Findings generated in the basic research arena have been rapidly in-
tegrated into clinically-based studies very often using methods that
would not be allowed to operate in the clinical laboratory. Further,
many of the published studies provide limited information on assay val-
idation or the use of fundamental laboratory techniques such as statisti-
cal quality control. Instead of adding to the accumulating number of
expert reviews on TBI biomarkers, we focused on identifying methods
used in the study of five of the most prominent biomarkers in the liter-
ature.We report on the limited amount of validation and quality control
data provided. In fairness, it is possible that the authors of the reviewed
publications completed a full, CLIA-approved validation for a high com-
plexity test with the use of established quality control ranges to validate
all publisheddata.More likely, the publications selected for review illus-
trate a pervasive lack of appreciation for the rigorous quality standards
required from clinical testing in an attempt to fulfill the promise of
translational research expectations.
The clinical laboratory continues to grow in its ability to transform
novel, highly complex research assays into routine clinical tests, while
at the same time more advanced technology continues to find its way
from research into the clinical laboratory. In addition, if sex and gender
influences are not fully understood TBI researchmay fail to address im-
portant issues pertaining to the assessment and treatment of TBI. Due to
a general ambiguity towards TBI in terms of definition, assessment, and
treatment [3] and the fact that 77% of individuals with TBI are male [5],
TBI research appears especially prone to gender bias. The subsequent
focus of this review is on the clinical approach to TBI, methods used in
TBI research, methods available in the modern clinical laboratory and
sex and gender differences in TBI biomarker studies.
Current clinical approach to TBI
TBI is a heterogeneous disease with numerous methods to classify
patients, most often into mild, moderate or severe TBI, based on clinical
severity, injury type and pathophysiology. The most commonly used
tool for the assessment of TBI is the Glasgow Coma Score (GCS) [6] in
addition to the inclusion of age, medical comorbidity and imaging
studies [7,8]. Ideal in its simplicity, criticism of the GCS for TBI classifica-
tion is based upon a number of confounding factors that may contribute
to a skewed score [9].
Mild traumatic brain injury
Mild traumatic brain injury (mTBI) is considerably more common
than moderate and severe TBI; however, a risk of serious and long
term complications can arise if adequate treatment is not provided.
mTBI most often occurs as a result of contact and/or the physical and
mechanical forces of acceleration and deceleration.
Concussion in athletics
A concussion is defined as a traumatically induced, transient distur-
bance of brain function. Concussion is correctly classified as an mTBI,
with an important distinction in that not all mTBIs are concussions [1].
In 2012, a consensus statement provided by the 4th International Confer-
ence on Concussion in Sport held in Zurich identified common features
useful in defining a concussion. These features include cause (direct
blow to the head or elsewhere that is transmitted to the head), acute
symptoms (short-lived impairment of neurologic function), neuropatho-
logical changes (due to functional and not structural changes often
missed by imaging studies), a grouping of clinical symptoms which may
or may not involve the loss of consciousness, and a step-wise resolution
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of those symptoms [10]. The hallmark symptoms of concussion include
confusion and amnesia,with headache and dizziness themost commonly
reported symptoms appearing minutes to hours post-injury. Symptoms
of severe concussion are non-specific and includenausea, vomiting, head-
ache, sleep disturbances and mood alterations [1].
Current estimates put the number of sports related concussions in
the US between 1.6 and 3.8 million per year [11]. Concussions are
more common in competition compared to practice, females compared
to males [12], and have a higher rate in collegiate compared to high
school athletes [13]. In general, concussions aremore common andhap-
pen at a higher rate in high impact sports such as football, wrestling,
soccer, and ice hockey [12], and are seen in higher risk positions on
the field such as a catcher in baseball, a linebacker or running back in
football, or a goalie in soccer [13]. Other risk factors for concussion in-
clude a prior concussion and younger age,while ADHD,mood disorders,
learning disorders, and migraine headaches can complicate concussion
symptoms and management [1]. The primary cause for the noticeable
increase in concussive events is not definitively known but is partly
attributed to increased awareness of prevalence and symptoms [14].
Management of concussion can be difficult as the approach to concus-
sion must be individualized for every person due to inter-individual var-
iation in rates of recovery. At a minimum, athletes should obtain a
preparticipation physical where a healthcare provider can evaluate the
athlete for any current or prior health issues including concussion. If con-
cussion has been an issue for an athlete in the past, additional information
should be obtained including, but not limited to, the number of prior con-
cussions, prior recovery, and when the last concussion was sustained.
More commonly, athletes are obtaining baseline testing through the use
of a sideline assessment tool, balance testing, or neuropsychological test-
ing at the beginning of the season in order to have comparative data after
an in-season concussion. Neuropsychological testing can be either com-
puterized or done by pencil and paper, and aims to evaluate the athlete
on areas like orientation, memory, reaction time, and concentration.
Given the fact that these measures have not been shown to affect short-
term or long-term outcomes from concussion, some controversy exists
about their utility. Where they do seem to be more useful is in athletes
where symptoms have resolved, but concern exists about full recovery.
A follow-up administration of a neuropsychological test could show
persistent deficits when compared to baseline testing, leading the pro-
vider to withhold the athlete until testing results in a return to baseline
scores [1].
Once a concussion is determined to be a possibility, on fieldmanage-
ment includes taking the player out of the game for further evaluation.
Generally, the athlete is taken through a sideline assessment tool,
designed to assess symptoms, orientation, balance, memory, and con-
centration. If it is determined that the athlete has had a concussion, he
or she is removed from play, and should not be allowed to return to
competition on the same day. Acute management may include symp-
tom management with medication for pain, avoidance of bright lights
or loud sounds, and physical and cognitive rest. Of note, it is no longer
advised to frequently wake a concussed individual or instruct the indi-
vidual to avoid sleep, as it largely considered a valuable component to
the healing process [1].
In general, advanced imaging for concussion is rarely needed, as the
results are typically normal. A clinicianmay proceed to advanced imag-
ing given the presence of more concerning signs such as seizures,
evidence of a skull fracture, or focal neurological deficits. CT is the mo-
dality of choice in the acute situation, but for prolonged symptoms an
MRI may be obtained [10,15]. More recently, imaging modalities like
functional MRI, diffusion tensor imaging, and MR spectroscopy are
being evaluated for their utility in concussion management with en-
couraging results, but definitive use has yet to be determined [1].
Development of equipment to protect athletes from injury is an evolv-
ing process. Helmets were originally created to reduce the incidence of
skull fractures, intracranial bleeding and oral and eye injuries. There is
no evidence that headgear reduces the incidence of concussion [1]. Over
40% of concussion symptoms have resolved in 3 days or less, and over
50% of athletes return to play betweenwithin 1 to 3 weeks. Unfortunate-
ly, approximately 20% of athletes will have symptoms longer than
3 weeks [12,16]. It is difficult to predict who will have profound or
prolonged symptoms, but certain signs at presentation have been associ-
ated with a worse prognosis. These include greater than 3 symptoms at
presentation, a feeling of fogginess, a headache lasting longer than 60 h,
and retrograde amnesia. Interestingly, loss of consciousness had no bear-
ing on prognosis [17,18]. It should be noted that a licensed healthcare
professional with concussion training should be the one to clear the
athlete for play, and more states are passing legislation making this a re-
quirement [1]. Return to activity should be performed in a stepwise
manner as outlined in Fig. 1. As the baseline step of the Return to Play
Progression, the athlete needs to have completed physical and cognitive
rest, and not be experiencing concussion symptoms for a minimum of
24 h. The overall goal of this stepwise approach is the return to competi-
tion once the athlete is asymptomatic. Keep in mind, the younger the
athlete the more conservative the treatment.
Complications in mTBI
The more serious outcomes from concussion can include post-
concussion syndrome (PCS), second impact syndrome (SIS), and chron-
ic traumatic encephalopathy (CTE). PCS is most often described in the
setting of mTBI, but its presentation varies widely, as does the criteria
for diagnosis. Typically, PCS refers to symptoms of concussion lasting
fromweeks tomonths. To date, no studies have shown a significant cor-
relation between severity of injury and PCS; however, past history of
concussion may be a risk factor for the development of PCS [19]. SIS
Fig. 1. Steps in the assessment for return to play decisions.
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occurs when an athlete returns to competition too soon and sustains
another concussion leading to significant sequela, including death
[15]. SIS is exceedingly rare and has only been found to occur in athletes
younger than 20 years of age. Finally, CTE is an increasingly recogniz-
able phenomena, where the accumulative effects of head trauma lead
to earlier symptoms of encephalopathy similar to what is seen in
Alzheimer's Disease [20].
Moderate/severe traumatic brain injury
The establishment of standardized approaches has led to major
advances in the treatment of moderate and severe TBI [4,21,22]. A
significant complication in treatment protocols for TBI is the high likeli-
hood of accompanying injuries to other organ systems as a result of
overall trauma. The initial goal for acute treatment is to prevent hypo-
tension and hypoxia to reduce the impact of secondary injury [23].
Assessment with the GCS may be helpful in guiding early intervention
with subsequent treatment involving general emergency management,
neurological examination, neuroimaging andpossible surgical interven-
tion [4,7,23]. Consistent monitoring of intracranial pressure, cerebral
perfusion, fever, glucose levels and prevention of thromboembolism
are all important aspects of the treatment for TBI [2,24].
Gender differences in treatment
Farace and Alves describe distinct forms of gender bias in published
research on TBI outcomes. Inmeta-analyzing gender differences in trau-
matic brain injury outcomes (e.g., death, persistent vegetative state, and
severe disability), the researchers reported that of the 9822 published
studies available, only 40 described separate outcomes for each sex
[25]. Thus, the authors concluded carefully that women fared worse in
85% of the measured variables [25]. Approximately a decade later, re-
searchers at the German Sports University Cologne confirmed the ten-
dency to ignore issues of sex and gender within sport and health
related research. A content analysis of journal publications in sports
medicine outlets identified only 7.2% of all studies that examined
gender/sex as a variable of interest [26,27]. Despite this trend, recent
studies indicate that there are significant differences in regard to the
epidemiology, diagnosis, and outcomes of TBI between women and
men. After examining discharge destinations of 3480 patients, Brown
et al. concluded that following TBI, womenwere significantlymore like-
ly than men to be sent to long-term care facilities rather than the in-
home setting [28]. Furthermore, differences in long-term disability or
life satisfaction following TBI have been reported between women and
men, with higher rates of post-concussion (women 50%, men 30%)
and disability (women 52%, mean 37%) for women [29]. Moreover,
Colantonio et al. [36] found evidence for very different support struc-
tures and resources available following release from an acute care set-
ting for female TBI survivors. With a special focus on TBI in the setting
of sports, Berz et al. reported that concussed female athletes at the age
between 9 and 17 years scored higher on the post-concussion symptom
scale compared to male athletes, suggesting that it may take longer for
young female athletes to recover following sports-related concussion
[30]. Likewise, high school and collegiate female athletes aremore likely
to suffer concussions compared to male athletes in analogous sports
such as soccer, basketball, baseball, softball and ice hockey [13,31–33].
Sex differences in medical outcomes following TBI
In addition to gender differences in acute clinical care settings and
with regard to psychosocial outcomes, several researchers have report-
ed sex differences in medical outcomes following TBI including death,
vegetative state, disability, and recovery. Many studies have linked sex
differences in medical TBI outcomes to sexual dimorphism or differ-
ences in brain structure and anatomy [34]. Studies focusing on stroke
risk and outcome revealed a protective effect of female sex hormones,
such as estrogen and progesterone, in the outcome between women
and men following TBI. However, sex differences in TBI have been
shown to persist after menopause and in the pediatric population.
This suggests that the impact of reproductive steroids may not exclu-
sively explain sexual dimorphism in brain injury [35]. Additionally, TBI
has been shown to affect the female cycle and its hormonal cascades
by depression of female sex hormones. Colantonio et al. found distur-
bances (e.g., amenorrhea) within the female cycle up to 60 months
after TBI [36]. Furthermore, in determining the causes of clinical depres-
sion following TBI, significant differences between women and men
have been found with respect to cognitive and emotional adjustment.
Women seem to experience higher levels of depression [5], more pain,
and report sleep disturbances when compared to men [37–39]. These
symptoms emerge with neuroendocrine dysfunction along with
pituitary-target hormone disruption following TBI [40,41]. Given the
critical correlation of psychosocial well-being and neuroendocrine
responses [42], early detection of abnormalities in TBI-specific neuroen-
docrine biomarkers is important. Neuroscience research over the last
decade has focused on cellular andmolecular based approaches to iden-
tify the mechanisms of TBI and to improve diagnosis and prognosis of
TBI. The difficulty lies in the identification of biological markers, which
relate to clinical symptomsof TBI and the need to address the lack of un-
derstanding of the contribution of gender and sex-specific aspects to TBI
biomarker discovery.
Limited laboratory support for TBI
A key component absent from the diagnosis andmanagement of TBI
is the use of clinical pathology laboratory results. Proposed blood-based
biomarkers for TBI assessment continue to be studied and reportedwith
little translation into routine clinical testing thus far. A recent review
highlights the numerous shortcomings of currently proposed TBI bio-
markers and is in agreement with the current review that greater
adherence to clinical standards in research is required to properly pres-
ent data to treating physicians [24]. In addition, an often overlooked as-
pect of blood-based biomarker research is the need for context specific
reference intervals andmedical decision points to enhance the sensitiv-
ity and specificity of putative biomarkers to a level required for their as-
similation into the clinical management of TBI patients. Lastly, and
perhaps most significantly, biomarker discovery in TBI has predomi-
nately focused on the acute stages of injury with little attention given
to the utility of blood-based biomarkers at later time points.
Methods available for clinical TBI assessment
Conventional clinical immunoassays
Principles
Antibody-based methods of detection are utilized across nearly all
divisions of laboratory medicine and a wide variety of platforms, detec-
tion methods and assay principles are available.
Automated platforms commonly utilize turbidimetry or nephe-
lometry for spectrophotometric-based methods, with either rate or
equilibrium measurements taken within a few minutes or up to an
hour, respectively, after the initiation of the reaction. Both methods
rely on the formed immune complex to scatter light and as a result
can suffer reduced signal-to-noise levels in specimens such as
serum with nonspecific light scattering due to high protein or lipid
concentrations.
Antibodies conjugated to various types of labels can be found in au-
tomated FDA, approved immunoassays as well as highly manual,
laboratory developed assays. Common labels used for detection include
enzymes, fluorophores and chemiluminescent compounds. Alkaline
phosphatase, β-D-galactosidase, glucose-6-phosphate dehydrogenase
and horseradish peroxidase can produce products measured most
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often by chemiluminescence and fluorescence with an inherent ampli-
fication of signal by the enzyme label.
Enzyme-Linked Immunosorbent Assay (ELISA) is an antibody-based
technique that has been widely used in clinical analyses for several de-
cades. Sandwich ELISAs make use of a capture antibody and a detection
antibody to form an antibody–antigen–antibody “sandwich”. Sandwich
ELISAs are best suited for large antigens such as proteins due to the re-
quirement of two, unique epitopes for capture and detection. Competi-
tive ELISAs are useful for the measurement of small targets such as
drugs and drug metabolites where multiple epitopes are not practical.
An enzyme-labeled target competes for binding to the capture antibody
with any endogenous, non-labeled target present in the sample.
Major limitations in antibody-based assays have been well docu-
mented [43,44]. On the one hand, broad cross-reactivity of the anti-
bodies used can enhance sensitivity by detecting multiple, structurally
similar antigens [45,46]. On the other hand, this same cross-reactivity
can result in poor specificity if non-related antigens are detected. In
the presence of high antigen concentrations, false negatives can occur
and is referred to as a “hook effect” while anti-reagent antibodies
present in the sample can result in both false negative and false positive
results. Reduction of these anti-reagent interactions requires the pres-
ence of non-immune serum or non-specific IgG from the same species
where the assay antibodieswere originally raised. Lastly,matrix compo-
nents can significantly impact the performance of a developed ELISA ne-
cessitating the independent validation of performance characteristics
across all desired specimen types and most often require the use of
matrix-matched calibrators and controls.
Utility in biomarker studies
The majority of immunoassay-based methods currently available in
the clinical laboratory provide independent analysis of each target of in-
terest. Required sample volumes for nephelometric, turbidimetric and
ELISA assays vary with limited capacity for multiplexed measurements.
As a result, investigating the five putative markers listed above would
requirefive separate aliquots of sample in addition to any excess sample
needed in the event that dilution or repeat testing is required.
Multiplexed immunoassays
A growing interest in the simultaneous measurement of multiple
analytes for diagnostic and prognostic purposes has immense implica-
tions for the clinical laboratory. Unfortunately, relatively few platforms
capable of multiplexed, antibody-based measurements of proteins or
small molecules have a significant presence in laboratory diagnostics
in comparison to traditional single target assays. Themultiplexed assays
that are available can be divided into planar and suspension micro-
sphere designs.
Principles
Planar immunoassays are similar in principle to the classic, single
target immunoassays routinely used in most clinical diagnostics. The
major differencewith amultiplexed format is the application of numer-
ous, unique microspots arranged in a reproducible, two-dimensional
layout with each microspot containing specific capture antibodies.
Each microspot will form an antibody–antigen–antibody sandwich
after addition of a detection antibody. Although each microspot has
the same method of detection, e.g., chemiluminescence, specificity of
the signal is imparted by the x,y location. Intensity of the signal is used
to determine concentration in quantitative assays through the use of a
standard curve. Not surprisingly, reproducibility in x,y position and the
amount of capture antibody deposited in themicrospot are of outstand-
ing concern and can introduce unwanted variability to the measure-
ment system.
Suspension microsphere immunoassays are by far the more
common design currently used for multiplexed antibody-based mea-
surements [47] and are based upon the principles of flow cytometry.
Capture antibodies are immobilized on unique microspheres that are
distinguishable by size or fluorescence. An antibody–antigen–antibody
sandwich will form through the use of a labeled detection antibody.
Each formed sandwichwill use the same type of label (e.g., fluorescence
of phycoerythrin) that is used to determine the amount of antigen in the
sample. The unique fluorescence signature of each bead present in the
multiplexed assay provides the means for identification. Quantitation
is possible by comparison of the resulting signal to that of a standard
curve. Uniformity of microsphere size, fluorescence signal, and the
amount of immobilized capture antibody are all possible sources of
variability.
Utility in biomarker studies
Multiplexed immunoassays are routinely used in biomarker studies
and have proven their utility in clinical diagnostic settings where mea-
surements of multiple analytes are needed [48,49]. In addition, a single,
simultaneousmeasurement is advantageous in situationswhere sample
volume is a limiting factor. The use of a multiplexed approach is not
without limitations, specifically in an environment as heavily regulated
as the clinical laboratory. High complexity testing requires a compre-
hensive method validation including characterization of accuracy,
intra and interassay imprecision, linearity, limits of detection, limits of
quantitation and recovery. Further, quality control procedures increase
in complexity in proportion to the degree of multiplexing. Matrix
matched, quality control materials at multiple levels for each analyte
are required in addition to established acceptability ranges for each.
Multiplexed assays present further complications in regard to quality
control acceptance criteria if one ormore QC results fail to meet expect-
ed criteria for some but not all analytes.
Mass spectrometry
Mass spectrometry has been a pioneering technology for the field of
laboratory medicine as nearly all disciplines from biochemical genetics
tomicrobiology have benefited from its introduction [50]. Sample prep-
arationmethods range froma simple dilution of a sample to highly com-
plex solid phase and liquid–liquid extractions. Gas chromatography and
liquid chromatography remain themost prominent separationmethods
prior to analysis by single quadrupole, triple quadrupole and time-of-
flight mass spectrometry [43].
Principles
In its simplest form, linear quadrupoles use a combination of radio-
frequency and direct currents to stabilize the flight path of gas phase
ions from the ionization source through a vacuum to the detector.
Continuously sweeping the voltage settings during the analysis allows
for all ions within an established mass to charge range (m over z or
m/z) to eventually reach the detector. Alternatively, discrete com-
binations of voltages can be used to allow only specific ions of a
predetermined m/z to reach the detector. Single quadrupole analysis
coupledwith gas chromatography remains a commonly used technique
for qualitative toxicology screens [51].
Triple quadrupole mass spectrometry is frequently referred to as
tandem mass spectrometry and is the technique of choice for clinical
laboratories conducting quantitative measurements with mass spec-
trometry [43]. Twomass filtering quadrupoles (Q1 and Q3) are situated
before and after a middle quadrupole collision cell (q2). At any given
time, voltages within Q1 are set to stabilize transmission of ions of a
singlem/z, q2 is filled with an inert gas causing collision induced disso-
ciation (fragmentation), while Q3 voltages are set to stabilize a single
fragment of a specific m/z. Specificity of tandem mass spectrometry
arises from the requirement of a given analyte to have the correct m/z
precursor ion and the correct m/z product ion. The combination of a
precursor and product ion is termed a transition and the majority of
clinical tandem mass spectrometry assays monitor one transition for
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quantitation and monitor separate transitions for qualification to fur-
ther enhance specificity.
Time-of-flight mass spectrometry is arguably the easiest form of
mass spectrometry to conceptualize but is less prominently used in
the majority of clinical mass spectrometry laboratories. Gas phase ions
within an entire m/z range are introduced into a high vacuum flight
tube by a uniform voltage. The resultant velocity of the ions is propor-
tional to their m/z ratio, with low m/z ions traveling faster than high
m/z ions towards the detector. Comparison to a reference solution
containing known compounds at specific m/z ratios provides the posi-
tive identification of the analyte of interest. Coupled to liquid or gas
chromatography, time-of-flight mass spectrometry provides a high-
resolution, high accuracy method for detecting large numbers of
analytes in a single sample. Time-of-flight mass spectrometry has
begun to be applied successfully for routine drug analysis in various
biological matrices [52–56].
Utility in biomarker studies
The majority of putative TBI biomarkers are large molecular weight
proteins at the same time that clinical protein analysis by mass
spectrometry is still currently out of reach for the average clinical
mass spectrometry laboratory [57,58]. The multiplex capability of
mass spectrometry has already been realized for small molecule
analysis and targeted approaches to clinical proteomics are being
actively pursued [59] and beginning their introduction into the clinical
laboratory [60]. Despite a clear advantage and successful application
in research and discovery, multiplexed analysis of putative biomarkers
in the clinical laboratory by mass spectrometry has yet to be fully
realized.
Point of care devices
The utility of point-of-care (POC) testing in laboratory medicine is a
continuously debated topic often focusing on ease of use, turn-around-
times, staff training requirements, central laboratory oversight, associ-
ated costs and increasing interest in accurately documenting clinical
outcomes associated with their use [61]. POC testing has become com-
monplace in hospital emergency locations for cardiac marker assess-
ment, coagulation and drug abuse testing in addition to glycemic
control both in the clinical setting and for personal use at home [62].
Although the controversies that surround POC testing are not likely to
be resolved easily or completely, the small, portable nature of a POC in-
strument together with the reduced requirement for sample volume
and faster TAT [63]make these devices attractive for in-the-field assess-
ments of TBI.
Principles
POC instruments vary considerably in complexity, analytical princi-
ple and overall size. The POC designs that are most relevant to TBI as-
sessment include lateral flow and cartridge or cassette devices and are
predominantly based upon similar principles to larger-scale sandwich
or competitive immunoassays discussed in the Principles section. One
key difference that can enhance the quality of the POC device is the in-
corporation of a built-in control to indicate successful operation of the
assay due to the predominantly single-use nature of POC testing.
Detection methods include visual observation by the operator, charge-
coupled device cameras, absorbance, surface plasmon resonance, eva-
nescent wave, fixed-polarized ellipsometry and diffraction [64–68].
The application of microfluidic technologies to POC testing provides a
potential mechanism for small volume, cost-effective measurement
across a wide range of applications [64].
Utility in biomarker studies
The availability of a portable, POC device for TBI assessment has
major applications into the exiting diagnostic workflow; however,
given even a near perfect POC device from an analytical standpoint the
success of such a device relies heavily on the utility of the incorporated
biomarkers. Numerous studies have been published on the application
of POC devices for TBI assessment and the need to move from a single
biomarker to a biomarker panel is widely appreciated [69]. Based upon
the recognized difficultieswith the transition of promising research find-
ings into a clinical TBI biomarker panel, it is unlikely that a single panel
will provide the required sensitivity and specificity to adequately serve
all categories of TBI across the wide array of affected populations.
Putative biomarkers for the assessment of TBI
The list of putative biomarkers for traumatic brain injury continues
to grow as does the conflicting results of their utility in various injury
paradigms. The most thoroughly investigated biomarkers to date in-
clude S100B, Neuron Specific Enolase (NSE), Glial Fibrillary Acidic
Protein (GFAP), Myelin Basic Protein (MBP), and Ubiquitin C-terminal
Hydrolase-L1 (UCH-L1). Each of these markers is discussed briefly in
the following sections with emphasis placed upon the reported perfor-
mance characteristics of the various methods used.
S100B
Outcomes and findings
S100B belongs to the calcium binding EF-hand protein group with
the origins of the family name based upon their solubility in a 100%
saturated solution of ammonium sulfate at neutral pH [70]. The diverse
roles of S100 proteins are still being identified in normal and abnormal
settings and extend beyond simple calcium sensing [71]. S100B has
compared favorably to CSF-serum albumin quotient, the gold standard
for assessing blood–brain barrier permeability [72]; however, other
studies have reported contradictory results [73,74]. The majority of
reviewed studies indicated that S100B measurement, either acutely or
at several timepoints, can distinguish injured fromnon-injured patients
[75,76] with an uncertain degree of utility in predictingmortality. Urine
measurements have been reported as an early predictor of short-term
mortality but perform no better than previously determined serum
measurements [77]. At present, S100Bhas largely become an acceptable
biomarker of TBI; however, studies have begun to highlight the need to
incorporate clinical symptoms instead of S100B concentration in isola-
tion on the basis of inconsistent results across published studies [78].
APOE genotype was observed to correlate withmaximal S100B concen-
tration [79], and the recent report of the presence of auto-antibodies in
the serum of football players with repeated blood–brain barrier disrup-
tion [80], based upon S100B measurements, illustrates the growing
complexity in the laboratory assessment of TBI.
Performance characteristics of identified methods
The reviewed studies listed in Table 1 reporting on the utility of
S100B predominantly used commercially developed immunoassays
using ELISA-based or variations of chemiluminescent-based detection.
Numerous studies made use of commercially available assays offered
on automated chemistry immunoassay analyzers, a clear indicator of
the prevalence and interest regarding S100B assessment. In addition,
two relatively recent publications are available comparing several, com-
mercially available immunoassays [81,82]. None of the reviewed assays
explicitly indicated complete verification of assay performance or the
use of quality controls and acceptability ranges. One assay cited valida-
tion data taken from the manufacturer and a separate study on the ac-
ceptability of the kit for use in urine measurements [77]. Of interest,
one cited publication concluded that results from two, independent
commercially available immunoassays were not interchangeable in
serum and provided no correlation whatsoever in urine [83]. One
assay established age specific reference intervals in 236 healthy children
using an automated immunoassay [84].
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Neuron specific enolase
Outcomes and findings
Neuron Specific Enolase (NSE) belongs to the superfamily of enolase
enzymes predominantly known for their glycolytic role but their impor-
tance in awide array of cellular functions and disease states continues to
unfold [85]. Alpha, beta and gamma enolase have all been implicated in
diverse pathologies consistent with their expression patterns and the
gamma isoenzyme has been studied extensively in TBI due to its in-
creased expression in neurons and cells of neuronal origin [85–87].
NSE in combinationwith S100Bhas been reported to aid in detecting in-
tracranial hemorrhage in mild TBI when used in conjunction with clin-
ical symptoms [78]. NSE on its own was reported to correlate with
Glasgow Coma Score formoderate and severe TBI withmodest sensitiv-
ity and specificity in predicting poor neurological outcomes [88]. The in-
corporation of NSE into a panel of biomarkers measured in CSF identified
severe TBI patients for up to three days post-injury [76]. In pediatric pa-
tients, measurement of NSE over time was used to develop trajectory
models for classification of outcome [89]. In direct comparison to other
proposed biomarkers of TBI, NSE proved useful but less so in the acute
phase of injury [90]. In the setting of mild TBI, a combination of NSE
with S100Bwas found to add value in early prognosis of patients [91]. Re-
cently, APOE genotypewas observed to correlate withmaximal NSE con-
centration; however, the finding was not statistically significant [79].
Performance characteristics of identified methods
The reviewed studies listed in Table 2 reporting on the utility of NSE
used commercially developed immunoassays using ELISA-based or var-
iations of chemiluminescent-based detection. The availability of com-
mercial NSE immunoassays is predominantly attributed to its role in
small-cell lung cancer [92,93], with onepublication available on theper-
formance characteristics of a commercially offered assay in the context
of its use as a diagnostic test for small-cell lung cancer [94]. Themajority
of reviewed publications provided no validation data, with one publica-
tion referencing work conducted in an animal model [76] and others
citing manufacturer claims. None of the reviewed assays explicitly indi-
cated complete verification of assay performance or the use of quality
controls and acceptability ranges. Of interest, one publication used a
shotgun proteomic approach to identify candidate targets from CSF of
severe TBI patients and identified several, prominent biomarkers
including NSE [95].
Glial fibrillary acidic protein
Outcomes and findings
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament
classically considered a marker of astrocyte reactivity with eight differ-
ent isoforms expressed across numerous subsets of astrocytes. Since its
initial days as an astrocytic-specific marker, GFAP has been shown to be
Table 1
S100B publications reviewed.
Publication Study description Reported method Validation data QC included Reported findings
Blyth et al. [138] Serum measurements
compared to CSF albumin
quotient
Monomeric transthyretin
also measured
ELISA (Nanogen, CA) Limit of detection Use of controls
referenced
Concentrations correlated with BBB
permeability
Kleindienst et al.
[139]
Prospective study using CSF
and serummeasurements
Electrochemiluminescence IA
(Roche Cobas e411)
Limited of detection
Analytical measurement
range
None referenced Concentrations in CSF and serum not
correlated with outcome
Concentration in serum not a
confirmed surrogate of BBB integrity
Pham et al. [74] Characterization of tissue
specificity for S100B serum
measurements
ELISA (DiaSorin, MN)
ELISA (Fujirebio Diagnostics,
Japan)
Electrochemiluminescence IA
(Roche Diagnostics, IN)
Limit of detection
Accuracy (Method
comparisons)
None referenced No relationship between serum
concentration and Body Mass Index
Characterization of CNS release of the
B–B homodimer of S100B
Vos et al. [99] Prospective study using serum
measurements
S100B also measured
STAT IntraOperative IA (Future
Diagnostics, Netherlands)
None provided None referenced Validation of previously established
cutoff concentrations
Correlation with outcome prediction
Bellander et al. [73] Prospective study using CSF
and serum measurements in
severe TBI
Complement system activation
and NSE also measured
Chemiluminometric IA
(DiaSorin, Italy)
None provided None referenced Complement activation parallels
increased S100B concentrations
Concentration in serum not a
confirmed surrogate of BBB integrity
No difference in acute S100B
concentrations between injury groups
Bohmer et al. [76] Prospective study of severe TBI
using CSF
NSE and GFAP also measured
ELISA (DiaSorin, Italy) Referenced Rainey
et al.[140]
Limit of detection
None referenced S100B concentrations were increased
compared to controls
Significant association between
concentration and clinical outcome
Bouvier et al. [84] Reference interval establishment
in children for S100B
Electrochemiluminescence IA
(Roche Diagnostics, IN)
Linearity
Intra-assay imprecision
Limit of detection
Referenced Alber et al.
[141]
None referenced Age specific reference intervals
established
Inverse correlation with head
circumference reported
Rodriguez-Rodriguez
et al. [77]
Prospective study using serum
and urine measurements
Electrochemiluminescence IA
(Roche Diagnostics, IN)
Referenced Hallen
et al. [83]
Imprecision (manufacturer
provided)
Limit of detection
Analytical measurement
range
None referenced Urine measurements used as a
predictor of mortality
Urine equivocal in predictive power
compared to serum
Wolf et al. [78] Predictive power assessment of
S100B concentration with
clinical symptoms
NSE also measured
Electrochemiluminescence IA
(Roche Diagnostics, IN)
None provided None referenced S100 concentration useful in
conjunction with clinical symptoms
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widely expressed in numerous cell types inside and outside the central
nervous system [96]. GFAP measurements have provided promising
data on injury pathway indication [97], focal versus diffuse injuries
[98], and prediction of morbidity and mortality [99–101] while other
studies provide a less positive outlook [102] or the need to measure
more specific break down products [103,104].
Performance characteristics of identified methods
The reviewed studies listed in Table 3 reporting on the utility of
GFAP used laboratory developed ELISA-based tests and one commer-
cially developed immunoassay. For several of the laboratory ELISA
tests, substantial validation datawas provided in the form of a reference
to the original method publication [99,100]. The publication containing
the greatest amount of method validation data provided a near com-
plete validation for a clinical assay conducted in a CLIA-certified labora-
tory [105]. None of the reviewed studies clearly indicated the use of
established quality control samples or acceptability ranges; however, a
single assay specified the use of a negative control [99]. Of note, several
studies reported on the detection of GFAP break down products (GFAP-
BDP) with one reviewed publication reporting on the cross reactivity
profile for the antibodies used in their specific laboratory developed
sandwich ELISA [103]. Of interest, one study in a cell culture injury
model measured GFAP by LC–MS/MS targeted quantitation using an
isotope dilution approach (IDA) [106].
Myelin basic protein
Outcomes and findings
Myelin Basic Protein (MBP) is a critical constituent of the insulating
myelin sheath surrounding axons. Though typically referred to as a
singular protein, there are numerous isoforms of MBP ranging from
14 kDa to 21.5 kDawith the predominate isoform varying amongst spe-
cies [107]. The interest in MBP as a biomarker of TBI has lessened in
comparison to S100B, NSE and GFAP in large part due to an observed
lack of clinical sensitivity [108].
Performance characteristics of identified methods
The reviewed studies listed in Table 4 reporting on the utility of MBP
used commercially available assays from both Canada and the United
States. No validation data was provided in any of the studies reviewed
nor was there reference made to quality control materials used during
sample analysis. Commercially available ELISA kits are typicallymarketed
as research use only (RUO) with the responsibility falling to the clinical
laboratory to verify any performance characteristics established and re-
ported by the manufacturer.
Ubiquitin C-terminal Hydrolase-L1
Outcomes and findings
Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) is an E2 ubiquitin-
conjugating enzyme expressed in neurons where it functions to add
and remove ubiquitin to proteins intended for degradation [109]. UCH-
L1 is one of the newest proposed biomarkers for TBI and as a result
there is limited data available to demonstrate its utility. The published
data suggest that UCH-L1 may be a useful serum biomarker for severe
TBI [110–112] and the ratio of GFAP toUCH-L1 in the serumhas beenpro-
posed as a method to determine focal versus diffuse TBI injuries [97,98].
Performance characteristics of identified methods
The reviewed studies listed in Table 5 reporting on the utility of
UCH-L1 used laboratory developed ELISA-based tests with validation
data predominantly resting on a single publication with limited impre-
cision, linearity and detection limit data in an animalmodel of TBI [113].
Of thefive publications reviewed three indicated theuse of internal con-
trols [97,98,112]. One publication provided evidence of recovery data by
comparing expected versus calculated calibrator concentrations andT
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Table 3
GFAP publications.
Publication Study description Reported method Validation data QC included Reported findings
Lumpkins et al. [101] Prospective study of severe TBI using serum ELISA (Biovendor, NC) None provided None referenced Persistent elevation after two days
predictive of increased mortality
Vos et al. [99] Prospective study using serummeasurements
S100B also measured
STAT IntraOperative IA (Future Diagnostics,
Netherlands)
From Vissers et al.[144] Controls without detectable GFAP Validation of previously established
cutoff concentrations
Correlation with outcome prediction
Wiesmann et al. [100] Prospective study using serum measurements
S100B also measured
Dissociation-enhanced lanthanide
fluorescence immunoassay (LDT)
Reference interval establishment
From Missler et al. [105]
Imprecision
Analytical measurement range
Accuracy (Method comparison to
ELISA — Van Geel et al., [145])
Linearity
Sample stability
Analytical measurement range
Recovery
Linearity
Intra- and interassay imprecision
Interferences (hemolysis, lipemia)
Hook effect
Sample stability
None referenced Elevated after trauma
Rapid decline in concentration
Bohmer et al. [76] Prospective study of severe TBI using CSF
NSE and S100B also measured
ELISA (LDT) From Tramontina et al.[146]
Analytical measurement range
Linearity
Interassay imprecision
Recovery
Interference (phosphorylated GFAP)
None referenced Acute GFAP assessment of limited utility
No significant association between
concentration and clinical outcome
Mondello et al. [97] Ratio to UCH-L1 ELISA (LDT) None provided Internal controls referenced GFAP/UCH-L1 N 1 observed in focal mass lesions
GFAP/UCH-L1 b 1 observed in diffuse injury
Mondello et al. [98] Prospective study using serummeasurements
Ratio to UCH-L1
ELISA (BioVendor, Czech Republic) None provided None referenced Biomarkers may be useful to determine
injury pathway
Metting et al. [102] Prospective study of mild TBI using serum ELISA (Biovendor GmbH, Germany) Limit of Detection
Intra-assay imprecision
Analytical measurement range
None referenced Correlation between concentration and
imaging studies
Not an independent factor of outcome
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imprecision of b10% and b15% for CSF and serum, respectively, using
this recovery data [111]. One study noted earlier measured UCH-L1 by
LC–MS/MS targeted quantitation using an isotope dilution approach
(IDA) in a cell culture injury model [106].
Gender differences in biomarker studies
Considerations of sex and gender in blood-based TBI biomarker performance
The sensitivity and specificity of any quantitative test are dependent
on the cut-off value above or belowwhich the test is positive [114]. Ac-
cordingly, disregarding sex/gender can lead to gender bias in TBI re-
search leading to test verification bias resulting in a lower observed
specificity of clinically appropriate TBI biomarkers [115].
Markers of TBI have distinctive features and cellular origins
representing a diversity of cellular injuries and injury patterns following
different types of primary injuries. The specific impacts of gender/sex
on the most common blood-based TBI biomarkers S100B, NSE, MBP,
GFAP, and UCH-L1 are not well investigated or documented. Even
though S100B is one of the most extensively studied biomarkers
[116,117], limited studies have focused on the influence of sex/gender
on the utility of this biomarker. In 1992, van Engelen et al. were the
first to examine whether age and sex were associated with an increase
of S100B levels in cerebrospinal fluid (CSF) [118]. Despite collection of
79 specimens of CSF from children and adults no sex dependency was
observed. Subsequently, Wiesmann et al. detected similar increases in
S100B plasma levels of healthy subjects between 18 and 25 years of
age but they could not confirm an effect of sex on alterations in S100B
levels within this age group [119]. In examining a younger population,
Gazzolo et al. investigated 1004 healthy children (males, n = 482;
females, n = 522) age 1 month to 15 years and found significantly
higher peripheral S100B concentrations in female pediatric patients
[120]. A relationship between age and sex was shown as well by Sannia
et al. aswas a dependency of S100B urine concentrations in late preterm
infants on the gestational age and infant's sex [121]. Even though sex
differences in healthy adults have not been confirmed, sex-specific dif-
ferences in the increase of serum S100B levels in adult depressive pa-
tients have been reported. Examination of 54 adult patients with
major depression found significantly higher serum S100B levels in fe-
male patients compared to male patients and confirmed the presence
of sexual dimorphism in altered neurophysiology [122].
Like the protein S100B, NSE is not secreted into extracellular space
under physiological conditions. However, NSE is detectable in extracel-
lular fluids after axon injury due to leakage and up-regulation in an at-
tempt tomaintain homeostasis [117]. Given its location and abundance,
NSE in body fluids should possess relatively high specificity and sensi-
tivity for axonal injury [117]. So far, clinical studies show no effect of
patient's sex on NSE levels in human biological fluids. Initially,
Abramson et al. [123] excluded sex-specific effects on NSE levels in
aqueous humor. Furthermore, NSE levels in the CSF of patients with
and without neurological disorders were observed to vary independent
of the patient sex [124-126]. Similarly, a study on CSF concentrations of
NSE in children and adults with diagnostic lumbar puncture found no
sex dependency but a relative increase of NSE with age was observed,
emphasizing the necessity of age-matched reference intervals [118].
Over the course of time, little influence of sex on NSE levels has been re-
ported for serum levels of epileptic and depressive patients [127] or lung
cancer patients [93,128]. Interestingly, a study by Nygaard et al. in 1998
demonstrated age- and sex-dependency of NSE concentrations in CSF, in-
creasing with age from 21 to 84 years and comparatively higher concen-
trations in male than in female patients with various surgical procedures
in spinal anesthesia [129]. This sex and age-related dependency of NSE
has not been shown elsewhere and the explanation for this finding re-
mains unclear.
In addition to S100B and NSE, UCH-L1 is one of the most widely
studied biomarkers for TBI [130]. To date, only a few studies have
Table 5
UCH-L1 publications reviewed.
Publication Study description Reported method Validation data QC included Reported findings
Brophy et al. [112] Comparison of CSF and
serum measurements
ELISA (LDT) From Liu et al. [113] (animal model)
Limited imprecision
Linearity
LOD (calculated)
Internal controls
referenced
Correlation between CSF and serum
Elevated in TBI compared to controls
Serum measurements correlated with
3 month survival
Papa et al. [110] Prospective study in CSF ELISA (LDT) None provided None indicated Elevated after severe TBI
24-hour concentration predictive of
6-week mortality
Mondello et al. [97] Serum measurements;
ratio to GFAP
ELISA (LDT) None provided Internal controls
referenced
GFAP/UCH-L1 N 1 observed in focal
mass lesions
GFAP/UCH-L1 b 1 observed in diffuse
injury
Mondello et al. [98] Prospective study using
serum measurements
Ratio to GFAP
ELISA (BioVendor,
Czech Republic)
None provided None referenced Biomarkers may be useful to determine
injury pathway
Mondello et al. [111] CSF and Serummeasurements
in severe TBI
ELISA (LDT) Recovery by calibration verification
Limited imprecision using recovery data
Internal controls
referenced
GCS score correlated with UCH-L1 in CSF
and serum
Table 4
MBP publications reviewed.
Publication Study description Reported method Validation data QC included Reported findings
Yamazaki et al. [147] Acute head injury
NSE also measured
Disequilibrium radioimmunoassay None provided None referenced Internal jugular and peripheral blood
concentrations equivocal
Berger et al. [148] Prospective study in children
NSE and S100B also measured
ELISA (SynX Pharma, ON, Canada) None provided None referenced MBP concentrations increased in
majority of pediatric TBI
Berger et al. [149] Prospective study in children
NSE and S100B also measured
ELISA (Nanogen Corp, CA) Established cutoff values per
Berger et al. [148]
None referenced Potential utility ofMBP as a screening
test for infant TBI
Berger et al. [150] Prospective study in children
NSE and S100B also measured
ELISA (Nanogen Corp, CA) Established cutoff values per
Berger et al. [148]
None referenced Biomarker peak time varied amongst
TBI type
Berger et al. [89] Trajectory analysis in children ELISA (International Point of Care, CA) None provided None referenced Outcome correlated with trajectory
of biomarkers
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described sex-specific aspects in regard to UCH-L1 levels in CSF or pe-
ripheral blood. In 2012 Mondello et al. evaluated the ratio between
GFAP and UCH-L1 concentrations (GNR) to investigate the relationship
of this ratio with neuroimaging profiles in patients with severe brain
trauma. They observed that GNR was independent of sex, age, GCS
score and the mechanism of injury [98].
Similar to S100B, NSE, and UCH-L1, peripheral levels of MBP appear
to be a very specificmarker of TBI although no results onMBP in CSF are
currently available [131]. In 1992, van Engelen et al. obtained reference
values for MBP in children and adults of different ages and both sexes
for the first time. They reported an increase of MBP in CSF with age
but no significant differences between female and male patients
between 7 months and 66 years of age [118].
Comparable to other TBI biomarkers, GFAP concentrations do not
seem to be influenced by sex at first glance. In a study to develop an
ELISA assay for human autoantibody to glial fibrillary acidic protein in
Alzheimer's disease, the titer of GFAP antibody showed no significant
correlation with age or with sex in the control serum [132]. Neverthe-
less, studies using animal models to demonstrate astroglial reactivity
showed sexual dimorphism in the distribution of GFAP indicating an in-
fluence of sex steroids [133–137].
Conclusion
In summary, a brief overview of common TBI biomarkers – S100B,
NSE, GFAP, MBP, and UCH-L1 – provides contradictory results in regard
to the overall utility in diagnostic and prognostic roles at the same
time highlighting the often overlooked influence of gender on bio-
marker performance. The growing consensus in society and health
sciences regarding the necessity to improve excellence in scientific
research by incorporating the categories of sex and gender into the re-
search design is accompanied by a need to fully validate the perfor-
mance of assays used in clinical research. The clinical laboratory has
an unprecedented number of new and long-standingmethods available
to aid in medical decision making and guide diagnosis. As sex and
gender aspects in blood-based TBI biomarker performance need
further attention, so too must a higher priority be given to the proper
validation of all research methods used in the clinical setting, the use
of quality control materials and the explicit incorporation of this data
into publications. Based upon the elegant array of methods currently
operating in clinical laboratories world-wide, it seems that the clinical
laboratory not only is ready for its role in TBI assessment but also is
poised to help lead by example in generating high quality, reproducible
data.
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